C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

PURPOSE Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer. To further explore this relationship, we investigated associations between MYC amplification and disease-free survival (DFS) in a similar adjuvant trastuzumab HER2-positive breast cancer trial-North Central Cancer Treatment Group (NCCTG) N9831. PATIENTS AND METHODS This analysis included 799 patients randomly assigned to receive chemotherapy alone or with concurrent trastuzumab on N9831. Fluorescence in situ hybridization (FISH) was performed by using a dual-probe mixture for MYC and centromere 8 (MYC:CEP8) on tissue microarrays. MYC amplification was prespecified as MYC:CEP8 ratio > 2.2 or average MYC copies/nucleus > 5.0. Exploratory variables included polysomy 8. RESULTS In comparing DFS (median follow-up, 4.0 years) between treatments, patients with MYC:CEP8 ratio ≤ 2.2 (n = 618; 77%) and > 2.2 (n = 181; 23%) had hazard ratios (HRs) of 0.46 (P < .001) and 0.67 (P = .33), respectively (interaction P = .38). Patients with MYC copies/nucleus ≤ 5.0 (n = 534; 67%) and > 5.0 (n = 265; 33%) had HRs of 0.52 (P = .002) and 0.48 (P = .02), respectively (interaction P = .94). Patients with MYC:CEP8 ratio < 1.3 with normal chromosome 8 copy number (n = 141; 18%) and ≥ 1.3 or < 1.3 with polysomy 8 (n = 658; 82%) had HRs of 0.66 (P = .28) and 0.44 (P < .001), respectively (interaction P = .23). Patients with MYC copies/nucleus < 2.5 (n = 130; 16%) and ≥ 2.5 (n = 669; 84%) had HRs of 1.07 (P = .87) and 0.42 (P < .001), respectively (interaction P = .05). CONCLUSION We did not confirm the B31 association between MYC amplification and additional trastuzumab benefit. Exploratory analyses revealed potential associations between alternative MYC/chromosome 8 copy number alterations and differential benefit of adjuvant trastuzumab.

[1]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[2]  F. Cardoso,et al.  Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. , 2009, Current cancer drug targets.

[3]  E. Perez,et al.  c-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831. , 2009 .

[4]  Olufunmilayo I Olopade,et al.  MYC in breast tumor progression , 2008, Expert review of anticancer therapy.

[5]  Y. Asmann,et al.  A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy , 2008, PloS one.

[6]  E. Perez,et al.  The concordance between NCCTG's and NSABP's C-myc FISH assays , 2008 .

[7]  Achim Tresch,et al.  Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer , 2007, Bioinform..

[8]  E. Perez,et al.  Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Perez,et al.  Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer , 2007 .

[10]  D. Krag,et al.  Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells , 2007, British Journal of Cancer.

[11]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[12]  J. Menéndez,et al.  Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Arteaga.  Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  David Levens,et al.  The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c‐myc expression , 2006, The EMBO journal.

[15]  Jun Yao,et al.  Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. , 2006, Cancer research.

[16]  E. Henson,et al.  Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression , 2006, Clinical Cancer Research.

[17]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[18]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[19]  Sehwan Han,et al.  c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. , 2005, Human pathology.

[20]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[21]  M. Eilers,et al.  Contributions of Myc to tumorigenesis. , 2002, Biochimica et biophysica acta.

[22]  D. Bostwick,et al.  Loss of p53 and c-myc Overrepresentation in Stage T2-3N1-3M0 Prostate Cancer are Potential Markers for Cancer Progression , 2002, Modern Pathology.

[23]  B. Trock,et al.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance , 2000, British Journal of Cancer.

[24]  D. Liao,et al.  c-Myc in breast cancer. , 2000, Endocrine-related cancer.

[25]  R. Neve,et al.  Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.

[26]  S. Deming,et al.  Cell cycle basis for the onset and progression of c-Myc-induced, TGFα-enhanced mouse mammary gland carcinogenesis , 2000, Oncogene.

[27]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[28]  I. Bièche,et al.  Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. , 1999, Cancer research.

[29]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[30]  M. Fernö,et al.  Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications , 1999, The Journal of pathology.

[31]  G. Corner,et al.  Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. , 1997, Cancer research.

[32]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.